BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22036815)

  • 1. [Prolactinoma treatment status in the cabergoline era].
    Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
    No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and therapeutic aspects of prolactinoma in men].
    Braucks GR; Naliato EC; Tabet AL; Gadelha MR; Violante AH
    Arq Neuropsiquiatr; 2003 Dec; 61(4):1004-10. PubMed ID: 14762607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transsphenoidal microsurgical results of female patients with prolactinomas.
    Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
    Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
    J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
    Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
    J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
    Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mean platelet volume in patients with prolactinoma.
    Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
    Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach to the Patient With Prolactinoma.
    Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of prolactinomas: what's new in 2010?].
    Sedda A; Meyer P
    Rev Med Suisse; 2011 Jan; 7(277):20-4. PubMed ID: 21309169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
    Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
    World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.